Jasper Therapeutics Inc Ordinary Shares JSPR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma
-
Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences
-
Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
Trading Information
- Previous Close Price
- $18.83
- Day Range
- $18.56–19.35
- 52-Week Range
- $4.00–31.01
- Bid/Ask
- $18.00 / $19.50
- Market Cap
- $284.13 Mil
- Volume/Avg
- 121,349 / 198,392
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 45
Comparables
Valuation
|
Metric
|
JSPR
|
ENGN
|
ABEO
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.83 | 1.27 | 3.60 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
JSPR
ENGN
ABEO
Financial Strength
|
Metric
|
JSPR
|
ENGN
|
ABEO
|
|---|---|---|---|
Quick Ratio | 10.63 | 19.16 | 7.38 |
Current Ratio | 10.79 | 19.52 | 7.48 |
Interest Coverage | — | −39.66 | −24.01 |
Quick Ratio
JSPR
ENGN
ABEO
Profitability
|
Metric
|
JSPR
|
ENGN
|
ABEO
|
|---|---|---|---|
Return on Assets (Normalized) | −50.56% | −28.25% | −62.37% |
Return on Equity (Normalized) | −58.00% | −42.14% | −221.38% |
Return on Invested Capital (Normalized) | −61.81% | −33.08% | −143.96% |
Return on Assets
JSPR
ENGN
ABEO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Nglgnyqsnl | Crxc | $524.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tvjvncv | Czvzck | $120.0 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lwcvfvryp | Byqxhy | $115.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kgmrbycph | Mmrmxlp | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Grwxjkx | Flfx | $32.4 Bil | |||
| BioNTech SE ADR
BNTX
| Gjcjlmmgq | Jjmn | $28.2 Bil | |||
| Moderna Inc
MRNA
| Dgjvnrlr | Yqfs | $25.7 Bil | |||
| United Therapeutics Corp
UTHR
| Zzzfvprm | Prxc | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Crgkywl | Nchchs | $13.4 Bil | |||
| Incyte Corp
INCY
| Xrrrjym | Vnhrrb | $12.7 Bil |
United States